Sumitomo Chemical invests in nucleic acid drug company Bonac

The investment is 4 billion Yen and expands Sumitomo’s share in the company to 19,55 %. Bonac is a specialist for modified RNA synthesis (Bonac nucleic acids) which exhibit good stability and may lead to novel mucleic acid drugs.

Bonac news release, September 26, 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny